451,597 Dianthus Therapeutics, Inc. $DNTH Shares Purchased by Assenagon Asset Management S.A.

Assenagon Asset Management S.A. lifted its position in Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) by 160.9% in the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 732,246 shares of the company's stock after purchasing an additional 451,597 shares during the period. Assenagon Asset Management S.A. owned 1.34% of Dianthus Therapeutics worth $64,474,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. First Horizon Corp bought a new position in shares of Dianthus Therapeutics during the 1st quarter worth $32,000. Caitong International Asset Management Co. Ltd purchased a new stake in Dianthus Therapeutics in the fourth quarter worth about $43,000. EFG International AG bought a new position in Dianthus Therapeutics during the 2nd quarter worth about $49,000. GAMMA Investing LLC grew its holdings in Dianthus Therapeutics by 83.6% during the 3rd quarter. GAMMA Investing LLC now owns 558 shares of the company's stock worth $49,000 after acquiring an additional 254 shares in the last quarter. Finally, Global Retirement Partners LLC bought a new position in Dianthus Therapeutics during the 2nd quarter worth about $93,000. Institutional investors own 47.53% of the company's stock.

Insider Activity at Dianthus Therapeutics

In other news, CAO Edward Carr sold 20,000 shares of the business's stock in a transaction that occurred on Thursday, September 17th. The stock was sold at an average price of $101.38, for a total value of $2,027,600.00. Following the completion of the sale, the chief accounting officer directly owned 20,000 shares in the company, valued at $2,027,600. The trade was a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, SVP Adam M. Veness sold 16,167 shares of the business's stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $110.38, for a total value of $1,784,513.46. Following the completion of the sale, the senior vice president owned 3,833 shares of the company's stock, valued at $423,086.54. This trade represents a 80.84% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 242,429 shares of company stock valued at $26,118,913 in the last ninety days. 3.02% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on DNTH shares. Truist Financial increased their price objective on shares of Dianthus Therapeutics from $110.00 to $128.00 and gave the company a "buy" rating in a research note on Thursday, August 6th. Citigroup began coverage on shares of Dianthus Therapeutics in a report on Friday, September 4th. They set a "buy" rating and a $156.00 price objective on the stock. Raymond James Financial reissued a "strong-buy" rating and issued a $131.00 price objective on shares of Dianthus Therapeutics in a research note on Wednesday, August 5th. JPMorgan Chase & Co. started coverage on Dianthus Therapeutics in a report on Friday, September 11th. They set an "overweight" rating and a $135.00 target price for the company. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Dianthus Therapeutics in a report on Thursday. One research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $129.83.

Dianthus Therapeutics Stock Performance

Shares of Dianthus Therapeutics stock opened at $72.09 on Friday. The firm has a 50-day simple moving average of $99.30 and a two-hundred day simple moving average of $94.28. The company has a market cap of $3.95 billion, a P/E ratio of -17.37 and a beta of 1.35. Dianthus Therapeutics, Inc. has a fifty-two week low of $32.22 and a fifty-two week high of $117.88.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last posted its earnings results on Tuesday, August 4th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.85) by ($0.05). Dianthus Therapeutics had a negative return on equity of 22.53% and a negative net margin of 10,096.95%. The firm had revenue of $0.76 million for the quarter, compared to analysts' expectations of $0.30 million. Equities research analysts forecast that Dianthus Therapeutics, Inc. will post -3.81 EPS for the current year.

Dianthus Therapeutics Profile

Dianthus Therapeutics, Inc is a clinical-stage biotechnology company focused on developing targeted antibody therapies for autoimmune diseases. The company's approach centers on selectively modulating the complement system, an immune pathway involved in inflammation and tissue damage, with the goal of creating treatments that may offer potent disease control and convenient dosing.

Dianthus' lead investigational product is DNTH103, a fully human monoclonal antibody designed to selectively inhibit activated C1s, a key protein in the classical complement pathway.

Want to see what other hedge funds are holding DNTH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.